市場調查報告書
商品編碼
1395828
智慧胰島素筆針全球市場規模、佔有率、產業趨勢分析報告:按可用性、按產品、按最終用戶、按地區、展望和預測,2023-2030 年Global Smart Insulin Pens Market Size, Share & Industry Trends Analysis Report By Usability, By Product, By End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Home Care Settings), By Regional Outlook and Forecast, 2023 - 2030 |
預計到 2030 年,智慧胰島素筆針市場規模將達到 1.998 億美元,預測期內年複合成長率為 10.5%。 2022年市場規模為79.78萬台,成長率為9.9%(2019-2022年)。
根據 KBV 基數矩陣中的分析,F. Hoffmann-La Roche Ltd 是該市場的先驅。 2021 年 4 月,F. Hoffmann La Roche 與諾和諾德建立合作夥伴關係,為糖尿病患者開發資料收集解決方案。根據這項合作關係,羅氏將把 mySugr 的日誌與諾和諾德的聯網連網型胰島素筆針整合,提供增強的資料集和改進的見解。諾和諾德公司、雅培實驗室和美敦力公司等公司是市場上的主要創新者。
COVID-19 影響分析
包括智慧胰島素筆針在內的醫療設備的生產和分銷受到了疫情導致的全球支援鏈中斷的影響。製造成本上升,導致缺貨延誤。大流行的經濟不確定性給個人和醫療保健系統造成了財務困難。然而,在大流行期間,最大限度地減少面對面互動的需要加速了遠端監控和遠端醫療解決方案的採用。這些筆具有連接功能,有助於促進遠端糖尿病管理和諮詢。因此,疫情對市場影響不大。
市場成長要素
對連接和即時監控設備的需求不斷成長
筆的互聯程度越來越高,用戶可以將其設備與智慧型手機和其他行動應用程式同步。這種連接可實現即時資料傳輸,使患者更輕鬆地追蹤其胰島素給藥並與醫療保健提供者共用相關資訊。此外,為了解決胰島素耗盡的問題,一些智慧筆還配備了一個感測器,用於監測藥筒中剩餘的胰島素量。此功能可讓用戶規劃及時補充並最大限度地減少意外胰島素短缺的風險。因此,醫療保健設備對連接和即時監控的需求不斷成長,也加速了對這些筆的需求。
對符合監管核准和標準的產品的需求增加
監管部門的核准和對標準的遵守可以增強消費者的信心。這些遵守行業標準並滿足監管要求的筆更有可能被患者和醫療保健提供者採用。此外,醫療保健提供者、保險公司和其他相關人員更有可能推薦和支持這些已獲得監管部門批准的筆。監管機構制定涵蓋設備設計、性能和製造流程的標準。這些標準確保了我們的筆始終如一的品質和可靠性。因此,監管核准和標準是市場成長的關鍵驅動力。
市場抑制因素
初期成本高且保險範圍有限
購買這些設備的初期成本可能會阻止對價格敏感或經濟拮据的糖尿病患者。購買智慧型胰島素筆的成本,尤其是具有尖端功能的先進第二代設備,可能成為許多潛在用戶使用的障礙。此外,技術先進的產品價格相對昂貴,因此並非所有保險公司都會報銷。在某些地區,保險公司可能只為這些筆提供部分承保或完全不承保。因此,有限的保險範圍和高昂的初期成本可能會成為普及這些筆的障礙,並阻礙市場成長。
可用性視角
根據易用性,市場可分為預填充型和可重複使用型。在2022年的市場中,可重複使用的細分市場呈現顯著的成長速度。可重複使用的筆比預裝筆產生的塑膠廢棄物更少,預裝筆需要在每個筆芯後處理整個設備。對於有環保意識的人來說,這可能是個重要因素。可重複使用的筆在給藥調整方面提供了更大的彈性,允許使用者自訂胰島素給藥以滿足他們的需求。可可重複使用筆的使用者可以從更廣泛的胰島素類型和品牌中進行選擇,從而為他們提供更多選擇,根據自己的需求客製化治療方案。
產品展望
依產品分類,市場分為第二代鋼筆和第一代鋼筆。第二代筆細分市場在2022年獲得了可觀的市場成長率。第二代筆提供了更先進的連接選項,包括與行動應用程式、雲端儲存和遠端監控系統的無縫整合。這使得能夠與醫療保健提供者、看護者和家庭成員進行即時資料共用。第二代筆的先進功能和以使用者為中心的設計加深了使用者的參與。這些好處增加了對這些產品的需求。
最終用戶前景
依最終用戶分類,市場分為醫院/診所、門診手術中心和家庭護理設施。在2022年的市場中,居家醫療領域獲得了很大的收益佔有率。由於世界上大多數糖尿病患者集中在老年人口,居家照護環境中的胰島素注射筆預計將在未來幾年獲得巨大的關注。在家使用胰島素筆可以幫助減少就診次數,並為患者節省大量金錢和時間。這些筆是在家給藥胰島素的最佳選擇,因為它們非常攜帶。
區域展望
從區域來看,我們對北美、歐洲、亞太地區和拉丁美洲地區的市場進行了分析。 2022 年,北美收益佔有率最大。北美對智慧胰島素筆針的需求增加是由於糖尿病盛行率不斷上升、該地區對數位健康解決方案的親和性、保險覆蓋範圍以及醫療保健專業人員對這些設備的推薦。此外,北美市場是醫療保健技術領域的創新和競爭中心。這種環境正在導致更先進和方便用戶使用的筆的開發,進一步刺激需求。
The Global Smart Insulin Pens Market size is expected to reach $199.8 million by 2030, rising at a market growth of 10.5% CAGR during the forecast period. In the year 2022, the market attained a volume of 797.8 thousand units experiencing a growth of 9.9% (2019-2022).
Consumers have been inclining towards devices that offer real-time insulin monitoring for better diabetes management. The Second generation smart insulin pens offer more advanced connectivity options, such as seamless integration with mobile apps, cloud storage, and remote monitoring systems which fulfils the need. Consequently, the second generation pens segment would account for nearly 40% of the total market share by 2030. These pens often have more sophisticated data analysis capabilities, allowing users to monitor trends in their insulin usage and glucose levels. The advanced features and user-centric design of second-generation pens foster greater user engagement. These benefits have increased the demand for these products.
The major strategies followed by the market participants are Partnerships as the key developmental strategy to keep pace with the changing demands of end users. For instance, in April, 2022, Ypsomed AG entered a partnership with Abbott, to develop automated insulin delivery solutions. The partnership reinforces the company's commitment to improving diabetes management for patients around the globe. Moreover, in May, 2021, Eli Lilly And Company came into partnership with Roche, to develop diabetes management solutions. Under the partnership, Eli Lilly And Company would combine its Tempo Pen and Tempo Smart Button with a compatible diabetes management platform offered by Roche to develop a comprehensive diabetes management solution for patients around the globe.
Based on the Analysis presented in the KBV Cardinal matrix; F. Hoffmann-La Roche Ltd is the forerunner in the Market. In April, 2021, F. Hoffmann-La Roche Ltd signed a partnership with Novo Nordisk, to develop solutions for data collection of diabetes patients. Under the partnership, Roche would integrate its mySugr's Logbook with Novo Nordisk's connected insulin pens to deliver an enhanced data set along with improved insights. Companies such as Novo Nordisk A/S, Abbott Laboratories and Medtronic PLC are some of the key innovators in Market.
COVID 19 Impact Analysis
Smart insulin pens and other medical device production and distribution were impacted by the pandemic's disruption of global supply chains. Production costs went up, and there were shortages and delays. Financial hardships for both individuals and healthcare systems resulted from the pandemic's economic uncertainty. However, the need to minimize in-person interactions during the pandemic accelerated the adoption of remote monitoring and telehealth solutions. These pens, equipped with connectivity features, played a role in facilitating remote diabetes management and consultations. Therefore, the pandemic had a moderate effect on the market.
Market Growth Factors
Growing demand for connectivity and real-time monitoring devices
The pens have become more interconnected, allowing users to sync their devices with smartphones and other mobile applications. This connectivity enables real-time data transfer, making it easier for patients to keep track of their insulin administration and share relevant information with their healthcare providers. Additionally, in an effort to address the challenge of insulin depletion, some smart pens incorporate sensors that monitor the amount of insulin remaining in the cartridge. This feature enables users to plan for timely refills, minimizing the risk of running out of insulin unexpectedly. Therefore, the rising demand for connectivity and real-time monitoring in healthcare devices is accelerating the demand for these pens as well.
Increasing demand for products meeting regulatory approvals and standards
Regulatory approvals and adherence to standards build consumer trust. Adhering to industry standards and meeting regulatory requirements, these pens are more likely to be adopted by patients and healthcare providers. Moreover, healthcare providers, insurers, and other stakeholders are more inclined to recommend and support these pens that have obtained regulatory clearance. Regulatory agencies establish standards encompassing device design, performance, and manufacturing processes. These standards ensure the consistent quality and reliability of the pens. Thus, regulatory approvals and standards are critical drivers of growth in the market.
Market Restraining Factors
High initial costs and limited insurance coverage
The upfront expense of acquiring these devices may deter individuals with diabetes who are price-sensitive or have limited financial resources. The cost of purchasing a smart insulin pen, particularly advanced second-generation devices with cutting-edge features, can be a barrier to access for many potential users. Moreover, not every insurance company reimburses for technologically advanced products as these are comparatively more expensive. In some regions, insurance providers may offer only partial or no coverage for these pens. Consequently, the limited insurance coverage and high initial cost are barriers to the widespread adoption of these pens and can hinder their market growth.
Usability Outlook
By usability, the market is divided into prefilled and reusable. The reusable segment garnered a remarkable growth rate in the market in 2022. Reusable pens generate less plastic waste than prefilled pens, which require the disposal of the entire device with each cartridge. For people who care about the environment, this may be a crucial factor. Reusable pens offer greater flexibility in dosage adjustment, allowing users to customize their insulin doses as needed, which may be particularly valuable for individuals with variable insulin requirements. Users of reusable pens can select from a broader range of insulin types and brands, giving them more options to tailor their treatment to their needs.
Product Outlook
Based on product, the market is characterized into second generation pens and first generation pens. The second generation pens segment procured a considerable growth rate in the market in 2022. Second-generation pens offer more advanced connectivity options, such as seamless integration with mobile apps, cloud storage, and remote monitoring systems. This enables real-time data sharing with healthcare providers, caregivers, and family members. The advanced features and user-centric design of second-generation pens foster greater user engagement. These benefits have increased the demand for these products.
End User Outlook
Based on end-user, the market is segmented into hospitals & clinics, ambulatory surgical centers, and home care settings. The home care settings segment acquired a substantial revenue share in the market in 2022. These pens for insulin delivery in homecare settings are expected to gain enormous traction in the upcoming years, as most of the world's diabetes cases are concentrated among the elderly population. Insulin pens used at home can help lower the number of hospital visits, saving patients a great deal of money and time. These pens are the best option for administering insulin at home because of their high level of portability.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded the largest revenue share in the market in 2022. The increasing demand for smart insulin pens in North America can be attributed to the growing prevalence of diabetes, the region's affinity for digital health solutions, insurance coverage, and the endorsement of these devices by healthcare professionals. Moreover, the North America market is a hub for innovation and competition in the healthcare technology sector. This environment has led to the development of more advanced and user-friendly pens, further stimulating demand.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Eli Lilly And Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emperra GmbH, Jiangsu Delfu Medical Device Co.,Ltd, Abbott Laboratories and Ypsomed AG
Strategies Deployed in Smart Insulin Pens Market
Oct-2023: Novo Nordisk A/S announced the acquisition of Biocorp, a French drug delivery device maker. The acquisition complements and strengthens Novo Nordisk's connected delivery solutions.
Sep-2023: Abbott Laboratories signed an agreement to acquire Bigfoot, a smart insulin management systems developer. The acquisition strengthens Abbott's capability to deliver improved diabetes management solutions.
Sep-2022: Medtronic PLC released the Smart MDI system, a glucose management system for patients who are going through multiple daily injections. The system leverages Medtronic's InPen smart insulin pen and Guardian 4 smart continuous glucose monitoring (CGM) system to deliver real-time glucose values and insulin doses.
Apr-2022: Ypsomed AG entered a partnership with Abbott, a medical device company, to develop automated insulin delivery solutions. The partnership reinforces the company's commitment to improving diabetes management for patients around the globe.
Mar-2022: Novo Nordisk A/S introduced NovoPen Echo Plus and NovoPen 6 smart self-injection insulin pens. The two pens are used to display dosing information and can be paired with a compatible app to send the information to healthcare professionals, thereby facilitating remote patient monitoring.
May-2021: Eli Lilly And Company came into partnership with Roche, a global pharmaceutical company, to develop diabetes management solutions. Under the partnership, Eli Lilly And Company would combine its Tempo Pen and Tempo Smart Button with a compatible diabetes management platform offered by Roche to develop a comprehensive diabetes management solution for patients around the globe.
Apr-2021: F. Hoffmann-La Roche Ltd signed a partnership with Novo Nordisk, a Danish pharmaceutical company, to develop solutions for data collection of diabetes patients. Under the partnership, Roche would integrate its mySugr's Logbook with Novo Nordisk's connected insulin pens to deliver an enhanced data set along with improved insights.
Market Segments covered in the Report:
By Usability (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Product
By End User (Volume, Thousand Units, Revenue, USD Million, 2019-30)
By Geography (Volume, Thousand Units, Revenue, USD Million, 2019-30)
Companies Profiled
Unique Offerings from KBV Research